Stockreport

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor anta [Read more]